Research programme: oxazolidinone antibacterials - Durata

Drug Profile

Research programme: oxazolidinone antibacterials - Durata

Alternative Names: PF-00422602; PF-00708093; PF-02341752; PF-987296; VIC-104742; VIC-104988; VIC-105277; VIC-105491; VIC-105518; VIC-105535; VIC-105836; VIC-106632; VIC-106675; VIC-106699; VIC-106734; VIC-106814; VIC-106822; VIC-106828; VIC-106841; VIC-106857; VIC-106871; VIC-106922; VIC-106935; VIC-106936; VIC-106976; VIC-106993; VRC-104203; VRC-104766; VRC-104811; VRC-3783; VRC-4104; VRC-4203; VRC-4530; VRC-4766; VRC-4811

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Pharmacia Corporation; Vicuron Pharmaceuticals
  • Developer Pfizer
  • Class Oxazolidinones
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Gram-positive infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Gram-positive-infections in USA
  • 06 Oct 2014 Durata Therapeutics enters into a definitive merger agreement with Actavis
  • 15 Sep 2009 Preclinical trials in Gram-positive infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top